Appointment aims to reinforce Bonus Biogroup's leadership at a pivotal moment as the company advances toward Phase 3 clinical trials for its two flagship therapies: BonoFill and MesenCure. HAIFA, Israel, July 14, 2025 - Bonus Biogroup (TASE: BONS), a late-stage biotechnology company priming immunomodulatory and regenerative mesenchymal stem cells (MSC)…

The Company is working to expand its indication to include patients who have respiratory distress from any cause, including acute respiratory distress syndrome (ARDS). MesenCure's market potential in all-cause ARDS in the United States alone could reach approximately $9.6 billion by 2030, according to Company estimates. TEL AVIV, Israel, February…